Johnson & Johnson Unit Files Application for Hypertension Drug
September 30 2020 - 7:48AM
Dow Jones News
By Matt Grossman
Johnson & Johnson subsidiary Janssen Pharmaceutical Cos. has
filed a new-drug application with the Food and Drug Administration
for injections of Uptravi to treat pulmonary arterial hypertension,
the company said Wednesday.
Uptravi, a selective prostacyclin IP receptor agonist, was
approved in 2015 in oral form to delay the progression of pulmonary
arterial hypertension and reduce the risk of hospitalization.
In a new Phase 3 study, in which patients switched between oral
and intravenous applications of Uptravi, patients tolerated the
switched delivery methods well without unexpected safety findings,
Johnson & Johnson said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
September 30, 2020 07:33 ET (11:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
